Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions

Recurrent or Metastatic, Advanced Solid Tumors

Interventions

DRUG

IMB071703 injection

Intratumoral injection

Trial Locations (1)

RECRUITING

Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai

All Listed Sponsors

lead

Beijng Immunoah Pharma Tech Co., Ltd.

INDUSTRY